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ABSTRACT 
Assays to monitor the metabolic state or nutrient uptake capacity of 
immune cells at a single cell level are increasingly in demand. One assay, 
used by many immunologists, employs 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-
4-yl)Amino)-2-Deoxyglucose (2-NBDG), a fluorescent analogue of 2-
deoxyglucose (2DG), as a substrate for glucose transporters. This molecule 
has been validated as a substrate for the glucose transporter Glut2 (Slc2a2) 
in mammalian cells but 2-NDBG selectivity for the glucose transporters 
expressed by T cells, Glut1 (Slc2a1) and Glut3 (Slc2a3), has never been 
explored. Nor has the possibility that 2-NBDG might bind to T cells that do 
not express glucose transporters been assessed. In this technical 
commentary we interrogate the specificity of 2-NBBG labelling as a 
readout for glucose transport in T lymphocytes. We compare flow 
cytometric 2-NBDG staining against well validated radiolabelled glucose 
transport assays in murine T cells. Our data show there can be a large 
discordance between glucose transport capacity and 2-NBDG labelling in 
T cells. We also find that 2-NBDG uptake into murine T cells is not inhibited 
by competitive substrates or facilitative glucose transporter inhibitors, nor 
can 2-NBDG competitively block glucose uptake in T cells. Collectively, 
these data argue that 2-NBDG uptake alone is not a reliable tool for the 
assessment of cellular glucose transport capacity.  
KEYWORDS: 2-NBDG; glucose uptake; T cells; T lymphocytes 
INTRODUCTION 
In recent years, there has been a focus on intracellular metabolic 
pathways, metabolites and their dynamic changes in immune cells. 
Alongside this there is greater awareness of how nutrient availability, and 
the ability of immune cells to uptake nutrients, impacts and regulates 
immune responses. In this context, proteomic studies have shown the 
expression of nutrient transporters in T cells is highly regulated by antigen 
and cytokines [1–3]. There have also been many studies using 
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radiolabelled substrates for both quantitative and kinetic assays of how 
immune cells modulate nutrient transport. For example, radiolabelled 2-
deoxyglucose has been used to quantify changes in glucose transport in 
antigen and cytokine stimulated T cells. Similarly, radiolabelled amino 
acids have been used to quantify amino acid transport in immune 
activated T cells [3–10].  
The use of radiolabelled glucose and amino acids has generated 
fundamental information regarding nutrient transporter dynamics, 
specificity and affinity in lymphocytes. However, radiolabelled tracer 
assays have their limitations; apart from specific equipment and training 
being required, radiolabelled uptake assays must be performed on whole 
populations and do not have the capacity to resolve changes happening in 
subpopulations or single cells present in a complex mixture of cells. 
Increasingly, it is recognised that there is a need for single cell assays that 
can monitor nutrient transport to further investigations into how immune 
cells change nutrient utilisation during immune responses. Addressing 
this, there is a recently described flow cytometry-based assay for System L 
mediated amino acid uptake [7]. This assay uses a fluorescent substrate to 
measure the amino acid transport capacity of single cells present in 
complex mixed populations or tissues[7,11,12]. In this context, there is also 
a widely used flow cytometry assay that uses 2-(N-(7-Nitrobenz-2-oxa-1,3-
diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG), a fluorescent analogue of 2-
deoxyglucose (2DG) to monitor glucose transporter expression by single 
cells. In generating fluorescent glucose analogues, the 
nitrobenzoxydiazoamino group (NBDG) replaces a hydroxyl group (-OH) 
of a glucose molecule. In 2-NBDG, it is the -OH of carbon 2 that is replaced, 
whereas in 6-NBDG, the -OH of carbon 6 is replaced with NBDG. This 
structural alteration perturbs the interaction between substrate and 
transporter, as modelled and described for 6-NBDG having much higher 
binding affinity to Glut1, compared with glucose, yet far slower 
transmembrane transport in astrocytes [13]. Initial characterisation and 
validation of 2-NBDG as a substrate for glucose transporters was done in 
E.coli and in these bacteria, 2-NBDG uptake by cell was effectively 
competed with D-glucose, partially blocked by galactose and fructose, but 
not blocked by L-glucose or sucrose [14]. Specifically, it has been shown 
that 2-NBDG uptake in bacteria is mediated by a mannose or a 
glucose/mannose transporter system [15]. Subsequent studies have looked 
to see if 2-NBDG could be used to monitor glucose transport in mammalian 
cells [16]. This work rigorously characterised Slc2a2 (Glut2) mediated 2-
NBDG transport in Cos1 cells and in MIN6 pancreatic beta cells. 
Importantly, the uptake of 2-NBDG in these cells was shown to be highly 
selective; it was competitively inhibited by excess D-glucose and blocked 
in the presence of cytochalasin B, a glucose transporter inhibitor [16]. In 
kidney cells 2-NBDG uptake was shown to be mediated by a sodium-
glucose linked transporter (SGLT), which is blocked by phlorizin with 
residual sodium independent transport blocked by cytochalasin B [17]. 2-
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NBDG uptake has since been used extensively as a readout for glucose 
uptake in a broad range of mammalian cell types including T lymphocytes 
[18–24]. Moreover, high 2-NBDG staining often correlates with glycolytic 
metabolic activity in activated CD8 T cells [25–28]. 
 
Figure 1. Expression profile of glucose transporters in T cells. Protein copy numbers of glucose 
transporters detected in naïve, 24 h activated (TCR) and effector murine CD4+ (TH1) and CD8+ (CTL) T cells. 
Data are from previously published proteomics data sets [2]. Mean protein copy numbers are estimated 
using the proteomic ruler protocol [16]. Error bars are mean+/− s.d of 3 biological replicates. nd = not 
detected. 
However, there has been very little validation of how well 2-NBDG 
performs as a glucose transporter substrate in T cells and the efficacy of 
this assay compared to the well validated 3H-2DG uptake assay has not 
been addressed. This is pertinent as it is essential to understand the extent 
to which 2-NBDG binds non-selectively to different lymphocyte 
populations and whether changes in T cell activation and possibly 
autofluorescence impact the sensitivity of the 2-NBDG uptake assay. It is 
also critical to assess the selectivity of 2-NBDG for the glucose transporters 
predominantly expressed by T cells; Slc2a1(Glut 1) and Slc2a3 (Glut 3). To 
determine which glucose transporters are expressed by murine T cells, we 
have interrogated published quantitative deep proteomic T cell data sets 
[2]. The data in Figure 1 show that T lymphocytes do not express Slc2a2 
(Glut 2) or other facilitative glucose transporter (SLC2) family members, 
nor do they express sodium-glucose cotransporter (SLC5) or other sugar 
transporters such as the SLC50 family (SWEETs). Accordingly, we 
compared the sensitivity of the fluorescent 2-NBDG uptake and 3H-2DG 
assay in different T cell populations including naive T cells before and 
after antigen receptor activation, effector CD8+ cytolytic T cells (CTL) and 
thymocyte subpopulations. 
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Figure 2. Comparison of 3H-2DG uptake and 2-NBDG labelling in T cells. (A) Uptake of 3H-2DG in purified 
P14 CD8+ T cells +/− TCR activation using cognate peptide (gp33) for 18 h. (B) Flow cytometry histograms 
show 2-NBDG labelling (50 μM, 10 min, 37 °C) of P14 CD8+ T cells +/− TCR activation using cognate peptide 
(gp33) for 18 h. 2-NBDG labelling is detected using bandwidth covering emission at 530/30 nm. (C) 
Histograms show 530 nm emission in thymocyte populations with (left) or without (right) 2-NBDG labelling 
(50 μM, 10 min, 37 °C). (D) Uptake of 3H-2DG in thymocytes (total thymus) or effector CTL. (E) Histograms 
show 2-NBDG labelling (detected at 530 nm; 50 μM, 10 min, 37 °C) of thymocytes (total thymus) or effector 
CTL. (A, D; radiolabelled uptakes performed in triplicate. Points indicate individual biological replicates. B, 
C, E; Mean fluorescent intensities (MFI) values are indicated on the histograms, data are representative from 
minimum 3 biological replicates.).  
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DISCREPANCIES BETWEEN 2-NBDG AND 3H-2DG TRANSPORT IN T 
CELLS  
Figure 2A shows the quantification of glucose transport in naive and 
antigen receptor activated CD8+ T cells using the 3H-2DG assay. These data 
show a 10-fold increase in glucose transport in antigen activated T cells 
compared to naive T cells. Figure 2B compares 2-NBDG binding to naive 
and antigen receptor activated T cells and shows that 2-NBDG binding to T 
cells is increased following immune activation; and activated T cells have 
a 5-fold higher level of 2-NBDG binding than naive T cells. Glucose 
transporter expression, as determined by proteomics data analysis, shows 
3000 copies of Slc2a1 and 5000 copies of Slc2a3 expressed in naive T cells 
versus 51,000 Slc2a1 and 25,000 Slc2a3 copies in antigen activated T cells: 
an overall 10-fold increase in glucose transporter expression (Figure 1). 
Thus, both the 3H-2DG and the 2-NBDG labelling data appear to correlate 
well with relative levels of expression of glucose transporters in these T 
cell populations.  
Next we measured the effectiveness of the 2-NBDG labelling assay in 
thymocytes. Radiolabelled glucose transport assays have shown that 
murine T cell progenitors in the DN3 stage of thymocyte development 
(CD4−CD8−CD44−CD25+) have low levels of glucose transport but once these 
cells undergo TCR β-selection and transit to DN4 thymocytes they 
upregulate glucose transport to fuel rapid self-renewal and differentiation 
into CD4+CD8+double-positive (DP) thymocytes. DPs return to a state of 
quiescence and have very low levels of glucose transport [10,29]. This 
pattern of high glucose uptake and Glut1 expression post TCR β-selection 
is also closely paralleled in human thymocytes [30]. Figure 2C shows 2-
NBDG staining in thymocytes and reveals that the highest levels of 2-NBDG 
labelling are present in DP thymocytes, and this is not due to heightened 
autofluorescence in DP cells. Thus in the thymus there is poor correlation 
between 2-NBDG labelling and glucose transport capacity. This 
discrepancy between 2-NBDG labelling and 3H-2DG uptake is further 
underlined when thymocyte uptake is compared with effector T cells. 
Effector CD8 T cells have high levels of 3H-2DG uptake compared with 
almost undetectable 3H-2DG uptake by thymocytes, which are 80–90% DP 
cells (Figure 2D). In comparison, flow cytometric analysis of 2-NBDG 
labelling shows very high levels of 2-NBDG staining on DP thymocytes, 
even higher than that seen in effector CD8 T cells (Figure 2E). 
2-NBDG UPTAKE IS NOT SENSITIVE TO GLUCOSE TRANSPORTER 
INHIBITION 
In subsequent experiments we used glucose transporter inhibitors or 
transporter substrate competition to interrogate the specificity of 2-NBDG 
uptake in T cells. Cytochalasin B binds strongly to the internal face of 
facilitative glucose transporters (Slc2a1, Slc2a2, Slc2a3 and Slc2a4) and 
blocks substrate import. 4,6-O-ethylidene-α-D-glucose (4,6-O) binds at an 
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exofacial (outer) site and efficiently blocks substrate binding to the 
transporter [31]. Non-radiolabelled 2-deoxyglucose (2DG) was used as a 
direct substrate competition for the radiolabelled 3H-2DG uptake; this 
competes with glucose for binding and transport. The data show that 
neither 4,6-O treatment, cold competition with excess 2DG or glucose 
decreased the high levels of 2-NBDG labelling seen in thymocytes (Figure 
3A). Nor did cytochalasin B treatment block 2-NBDG staining in the 
thymocytes, although there was a consistent small reduction in uptake 
(Figure 3A). In comparison, Figure 3B shows that 3H-2DG uptake into 
effector T cells is efficiently blocked by cytochalasin B, 4,6-O and 2-DG. 
Whereas, 2-NBDG staining of effector T cells is not inhibited by 
cytochalasin B, 4,6-O or 2-DG (Figure 3C). In further experiments we 
assessed the impact of increasing the ratio of competitor/inhibitor relative 
to 2-NBDG in the uptake assays. There was no detectable 2-NBDG staining 
below 1 μM 2-NBDG (Figure 3D). At no point did glucose transporter 
inhibition with either cytochalasin B (Figure 3E) or 4,6-O (Figure 3F) block 
the 2-NBDG signal. There was a very small shift in CTL fluorescence in the 
presence of 50 mM 2-DG. This small reduction in fluorescence was not, 
however, specific to 2-NBDG uptake as this was present in unstained cells 
as well (Figure 3G). An explanation for this effect of 2DG on cell 
autofluorescence is that 2DG, which is known to interfere with glucose 
metabolism and glycolysis in T cells, could impact/perturb the NAD(P)H 
autofluorescence normally seen in highly glycolytic cells. This highlights 
another point of caution when interpreting subtle changes in fluorescence 
whilst using dyes that are detected in the region of cellular 
autofluorescence: you need to be certain that these differences are due to 
the amount of dye and not due to altered cellular autofluorescence. 
Collectively these data show a disconnect between radiolabelled 2DG 
transport and 2-NBDG transport in T cells and argue that glucose transport 
and 2-NBDG uptake are not mediated by a common transporter. Further 
evidence for this concept comes from experiments where 2-NBDG was not 
able to compete 3H-2DG uptake by activated T cells (Figure 3B).  
DISCUSSION  
In summary, the present data show that 2-NBDG labelling can correlate 
with metabolically active cells; e.g., activated T cells have higher 2-NBDG 
staining than naïve T cells. However, this is not always the case and we 
have observed the highest levels of 2-NBDG staining in non-metabolically 
active CD4+CD8+double-positive (DP) thymocytes that have very low levels 
of glucose transport. Moreover, in order for a substrate to be a reporter 
for glucose transporter activity, it should conform to relevant transporter 
dynamics. It is of note to recognise that initial testing and characterisation 
of 2-NBDG in mammalian cells used clear parameters to validate transport 
specificity; cytochalasin B treatment or competitive substrate assays thus 
led to inhibition of 2-NBDG transport [13,16]. Herein we have applied these 
parameters to 2-NBDG labelling of T cells and the data show clearly that 2-
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NBDG staining of murine thymocytes and effector CD8+ T cells does not 
follow simple glucose transporter principles: it is not out-competed by 
substrates, nor is it blocked by transporter inhibition.  
 
Figure 3. Glucose transporter inhibition does not block 2-NBDG labelling in T cells. (A) Histograms show 
2-NBDG labelling (detected at 530 nm) of thymocytes (total thymus) in the presence or absence of 2DG (50 
mM), 4,6-O-ethylidene-α-D-glucose (4,6-O; 20 mM) or cytochalasin B (CytB; 10 μM). (B) Percentage of 3H-2DG 
uptake in effector CTL inhibited by 2DG (5 mM), 4,6-O-ethylidene-α-D-glucose (4,6-O; 20 mM), cytochalasin B 
(CytB;10 μM) or 2-NBDG (5 mM). (C) Histograms show 2-NBDG labelling (detected at 530 nm) of effector CTL 
in the presence or absence of 2DG (50 mM), 4,6-O-ethylidene-α-D-glucose (4,6-O; 20 mM) or cytochalasin B 
(CytB;10 μM). (D) Histograms show 2-NBDG labelling (detected at 530 nm) of effector CTL after incubation 
with 100 nM, 1 μM or 10 μM 2-NBDG for 30 min. (E–G) Histograms show 2-NBDG labelling (detected at 530 
nm) of effector CTL after incubation with 100 nM, 1 μM or 10 μM 2-NBDG for 30 min in the presence or 
absence of fixed concentrations of glucose transport inhibitors: CytB (10 μM; E), 4,6-O (20 mM; F) or 2DG (50 
mM; G). (A, C–G; MFI values are indicated on the histograms, data are representative from 3 independent 
experiments. b; radiolabelled uptakes performed in triplicate). 
 
Immunometabolism 8 of 13 
Immunometabolism. 2020;2(4):e200029. https://doi.org/10.20900/immunometab20200029 
It is noteworthy that the discrepancy between NBDG analogue uptake 
and bonafide 2DG or glucose uptake has been previously noted [13,32]. 
Barros et al used mathematical modelling to address the disparity between 
the rates of glucose and 6-NBDG uptake in astrocytes as well as the 
insensitivity of 6-NBDG uptake to either glucose competition or 
cytochalasin B inhibition [13]. Their proposed model describes that 6-
NBDG binds to GLUT1 with 300 times higher affinity than glucose, but is 
not efficiently translocated, remaining on the exofacial surface of the cell. 
Thus, inhibitors which bind the exofacial aspect of glucose transporters 
would be predicted to be more effective at blocking NBDG import/labelling 
than endofacial inhibitors. Our data presented herein shows that whilst 
exofacial inhibition using 4,6-O does block radiolabelled 2DG uptake, it 
does not inhibit 2-NBDG accumulation in T cells. This and the fact that 2-
NBDG cannot competitively prevent glucose transport by activated T cells 
brings into question the validity of 2-NBDG as a tool to monitor glucose 
transport. Assays for nutrient transport have to incorporate relevant 
transporter controls, ensuring specificity and selectivity in the system. The 
lack of appropriate controls to verify the specificity of the 2-NBDG assay is 
a problem. Moreover, the high binding of 2-NBDG to thymocytes highlights 
the potential for 2-NBDG assays to misinform about cellular glucose 
transport activity. If thymocytes can have high uptake of 2-NBDG with no 
discernible capacity to transport glucose, then how many other leucocyte 
populations show a similar disconnect? These data highlight that 2-NBDG 
uptake assays should be interpreted cautiously and conclusions about 
cellular glucose transport capacity based on NBDG modified glucose 
uptake should only be made when the experiments include appropriate 
controls.  
MATERIALS AND METHODS 
Mice and Cells  
C57BL/6 (wild-type, WT) and P14 TCR [33] transgenic mice were bred 
and maintained in the WTB/RUTG, University of Dundee in compliance 
with UK Home Office Animals (Scientific Procedures) Act 1986 guidelines. 
All studies were performed on project license PPL60/4488 (Granted: 2013–
March-21) or P4BD0CE74 (Granted: 2018-March-21), approved by the 
University of Dundee Welfare and Ethical Use of Animals Committee and 
in compliance with UK Home Office Animals (Scientific Procedures) Act 
1986 guidelines.  
For naïve and TCR activated cells, lymph nodes from P14 TCR 
transgenic mice were removed and disaggregated. For TCR activated cells, 
lymph node suspensions were stimulated with cognate antigenic peptide 
(glycoprotein amino acids 33–41 (GP33); 100 ng/mL) in the presence of 
cytokines IL12 (10 ng/mL; RnD Systems, Abingdon, UK) and 20 ng/mL IL2 
(20 ng/mL; Proleukin, Novartis, London, UK). Cells were cultured in RPMI 
1640 containing L-glutamine (cat# 11875093, Gibco, ThermoFisher 
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Scientific, UK), 10% FBS (cat#26140087, Gibco, ThermoFisher Scientific, 
UK), 50 μM β-mercaptoethanol (cat#31350010, β-ME, Gibco, Sigma-Aldrich, 
UK) and penicillin/streptomycin (cat#15070063, Gibco, ThermoFisher 
Scientific, UK). Prior to radiolabelled uptake, CD8+ T cells were isolated 
using a magnetic bead negative selection kit (cat#19853, EasySep, 
STEMCELL Technologies, Cambridge, UK). To generate effector CTL, 
spleens were extracted from P14 mice and mashed in red blood cell lysis 
buffer before being suspended in RPMI media supplemented with GP33 
peptide (100 ng/mL) and IL-2 (20 ng/mL) and IL-12 (10 ng/mL) for 48 h. 
Subsequently, cells were washed out of activation media and then 
cultured for a further 3 days in media supplemented with IL-2 (20 ng/mL) 
and IL-12 (2 ng/mL), cells were maintained at 2 × 105 per mL. Cells were 
incubated at 37 °C with 5% CO2 throughout. 
To isolate thymocytes, thymi from 6–8 week old WT mice were removed 
and disaggregated. Cells were resuspended in RPMI 1640 containing L-
glutamine, 10% FBS, 50 μM β-ME and penicillin/streptomycin. 
Radiolabelled 2-Deoxyglucose Uptake 
Briefly, [3H]-2-deoxyglucose (3H-2DG, cat#NET328A; Perkin Elmer, 
Beaconsfield, UK) uptake was carried out using 1 × 106 cells resuspended 
in 0.4 mL uptake medium. Each uptake for a biological replicate is 
performed in triplicate. 3H-2DG uptake was carried out in glucose free 
RPMI (cat#11879020, ThermoFisher Scientific, UK) containing 3H-2DG (1 
μci/ml). 4 min uptake assays were carried out layered over 0.5 mL of 1:1 
silicone oil (Dow Corning 550 (BDH silicone products; specific density, 1.07 
g/mL: Cat#175633, Sigma-Aldrich, UK):dibutyl phthalate (Cat#524980, 
Sigma-Aldrich, UK). Cells were pelleted below the oil, the aqueous 
supernatant solution, followed by the silicone oil/dibutyl phthalate 
mixture was aspirated, and the cell pellet underneath resuspended in 200 
μL NaOH (1 M) and β-radioactivity measured by liquid scintillation 
counting in a Beckman LS 6500 Multi-Purpose Scintillation Counter 
(scintillant Optiphase HiSafe 3, cat#1200.437; PerkinElmer, Beaconsfield, 
UK). Where indicated, 5 mM 2-deoxyglucose (2DG, cat#D6134; Sigma-
Aldrich, UK), 5 mM 2-NBDG (cat#N13195, ThermoFisher Scientific, UK), 20 
mM 4,6-O-ethylidene-α-D-glucose (4,6-O, cat#E32754; Sigma-Aldrich, UK) or 
10 μM cytochalasin B (CytB, cat#C6762; Sigma-Aldrich, UK), were used 
respectively to inhibit radiolabelled ligand uptake. 
Flow Cytometry  
2-NBDG labelling: 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-
Deoxyglucose (2-NBDG, cat#N13195; ThermoFisher Scientific, UK) was 
stored as a 10 mM stock solution. Unless otherwise indicated, the data 
presented show T cell 2-NBDG labelling performed at a final concentration 
of 50 μM in glucose free RPMI at 37 °C for 10 min. (Longer time courses, 
with higher and lower concentration have been performed, data not 
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shown.) Where indicated, 50 mM 2DG, 20 mM 4,6-O or 10 μM CytB were 
used respectively to inhibit glucose transporter function. 
Thymocyte staining and gating strategy: Cell surface staining of 
isolated thymocytes was performed with CD4-Alexa 700 (RM4-5, 
cat#116022) CD8a-BV421 (53–67, cat#100737), CD25-PECy7 (PC61, 
cat#102016) and CD44-BV510 (IM7, cat#103043). Antibodies from 
BioLegend, UK. DN3 cells were identified as CD4− CD8− CD44− CD25+; DN4 
cells were identified as CD4− CD8- CD44− CD25−; DP cells were identified as 
CD4+ CD8+; CD4+ cells were identified as CD4+ CD8− and CD8+ cells were 
identified as CD4− CD8+. 
Data were acquired on a LSR Fortessa II with DIVA software or a 
FACSVerse flow cytometer with FACSuite software (BD Biosciences-
Europe, Oxford, UK) and analyzed using FlowJo software (for Mac, version 
9 and 10, Treestar; BD Biosciences-Europe, Oxford, UK). 
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